Refractory Angina Market Current Scenario and Future Growth Analysis by 2030 – Key Companies: Imbria Pharmaceuticals, Caladrius Biosciences, Angionetics Inc and XyloCor Therapeutics | Delveinsight

Refractory Angina Market Current Scenario and Future Growth Analysis by 2030 - Key Companies: Imbria Pharmaceuticals, Caladrius Biosciences, Angionetics Inc and XyloCor Therapeutics | Delveinsight

“Refractory Angina Market”

DelveInsight’s Refractory Angina Market Analysis Report proffers a comprehensive outlay of the Refractory Angina Epidemiological analysis focusing on the incidence and diagnosed patient pool segmented on the basis of several factors, as well as the Refractory Anginamarket analysis in the 7MM (the US, EU5 (the UK, France, Germany, Italy and Spain) and Japan).

The report covers the Refractory Angina market trends covering key pharmaceutical companies in the market, upcoming as well as Refractory Angina marketed therapies, unmet needs, prevailing constraints and the factors driving the market size growth. 


Some of the key highlights from the Refractory Angina Market Report:

  • The incidence/prevalence for Refractory Angina is growing significantly with a decent CAGR.
  • Refractory Angina market size was estimated as USD 2050.6 million in 2020.
  • Among the 7MM, the US accounted for highest market share of the overall market size of Refractory Angina in 2020.
  • Among the EU-5 countries, Germany accounted for the largest market size for Refractory Angina, followed by UK, France, Italy, and Spain.



Get more comprehensive insights into how Refractory Angina epidemiological trends are impacting current and forecasted Refractory Angina market @ Refractory Angina Epidemiology Analysis and Forecast


Some of the key companies working on Refractory Angina are:

  • Imbria Pharmaceuticals
  • Caladrius Biosciences, Inc.
  • Angionetics Inc.
  • XyloCor Therapeutics, Inc.

And Many Others.


Do you want to know how much market share the emerging therapies are going to capture by 2030? ContactRefractory Angina Marketed Therapies and Treatment Approaches and get a comprehensive understanding of the Refractory Angina therapeutic outlook


Scope of the report:

1. Refractory Angina market report covers a descriptive overview and comprehensive insight of the Refractory Angina epidemiology and Refractory Angina market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. Refractory Angina market report provides insights on the current and emerging therapies. 

3. Refractory Angina market report offers a global historical and forecasted market covering drug outreach in 7MM.

4. Refractory Angina market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Refractory Angina market.


Refractory Angina (RA) is a chronic condition where pain remain persistent for the duration of less than or equal to 3 months, characterized by angina. Angina is a type of chest pain caused by reduced blood flow to the heart. Angina has two types, chronic or stable angina and unstable angina. Around 10–15% of patients of Chronic Angina meet the measures of RA. The clinical load of RA is growing rapidly due to an ageing population and improved Coronary Artery Disease (CAD). 

Symptoms of RA are chest pain, shortness of breath, and easy fatigability. RA also shows neurological, psychogenic and mitochondrial dysfunctions in addition to tissue ischemia which are responsible for an insistent cardiac pain. These symptoms causes poor self-perceived health status, high incidence of depression, and burden to the health care system due to significant resource utilization.

Patients with RA are a heterogeneous group that remain significantly limited by persistent debilitating chest discomfort despite optimal conventional therapy.


 “According the DelveInsight, higher Prevalence of Refractory Angina is observed among males as compared to females in 7MM.”


Visit to know more about the indication, treatment algorithms in different geographies and patient journey contact to receive sample @ Refractory Angina Signs, Symptoms, Diagnosis and Treatment 

“RA is classified on the basis of grading the pain. Among these sub-types, Class III contributes the major patient share of RA followed by Class IV angina.”


The launch of the emerging therapies is expected to significantly impact the Refractory Angina treatment scenario in the upcoming years:-

Some of Refractory Angina Drugs Covered:

  • IMB-101
  • Auto CD34+ Cells
  • Generx
  • XC001

And Many Others.



Know more about the collaborations, tie-ups, and therapies launch @ Refractory Angina Pipeline Therapies and Forecast 


Table of Contents:

1. Refractory Angina Key Insights

2. Executive Summary of Refractory Angina

3. Competitive Intelligence Analysis for Refractory Angina

4. Refractory Angina: Market Overview at a Glance

5. Refractory Angina: Disease Background and Overview

6. Refractory Angina Patient Journey

7. Refractory Angina Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Refractory Angina Unmet Needs

10. Key Endpoints of Refractory Angina Treatment

11. Refractory Angina Marketed Products

12. Refractory Angina Emerging Therapies

13. Refractory Angina: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Refractory Angina Market Outlook

16. Access and Reimbursement Overview of Refractory Angina

17. Refractory Angina KOL Views

18. Refractory Angina Market Drivers

19. Refractory Angina Market Barriers

20. Appendix

21. DelveInsight Capabilities


Get in touch with our Business Executive @ Refractory Angina Market Outlook in the Next Decade


DelveInsght’s Competitive Intelligence Service includes a multidimensional coverage, helping to keep track of competitors and gain traction in the dynamic market by overcoming the challenges and expediting business growth through a strategic and tactical approach.   


About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States